The company, founded in 2019 and based in Oxford, UK, is a spinout from the University of Oxford and has laboratories located at the Harwell Campus in Oxfordshire. GyreOx's platform technology combines chemistry and synthetic biology to rapidly access novel and drug-like gyrocycles for hit-to-lead drug discovery. The proprietary discovery platform creates highly modified macrocyclic compounds called 'gyrocycles', which have the target-engagement power of biologics and the cell-entry ability of small molecules. This technology is protected by 4 patent applications and has the potential to bring new therapeutics to patients.